Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials
Sumit Sharma(Duke University), Glenn J. Jaffe(The University of Texas Health Science Center at San Antonio), Ebenezer Daniel(University of Pennsylvania), Gui‐Shuang Ying(Philadelphia College of Osteopathic Medicine), Juan E. Grunwald(University of Pennsylvania), Cynthia A. Toth(Duke University), Maureen G. Maguire(University of Pennsylvania), Jiayan Huang(University of Pennsylvania), Daniel Martín(Cleveland Eye Clinic)
Cited by 228
Related Papers
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
|Ophthalmology|2012|1.7k
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|857
Diabetic Retinopathy Preferred Practice Pattern®
|Ophthalmology|2019|703
Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration
|Ophthalmology|2016|702
Adalimumab in Patients with Active Noninfectious Uveitis
|New England Journal of Medicine|2016|646